Eric Dobmeier - 29 Apr 2025 Form 4 Insider Report for Jade Biosciences, Inc. (JBIO)

Reporting relationship: Director
Issuer ticker: JBIO
Reported as of: 29 Apr 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 May 2025, 18:00:21 UTC
Prior SEC filing: 01 May 2025
Next SEC filing: 13 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Balta, as attorney-in-fact for Eric Dobmeier

Key filing fact

Eric Dobmeier filed Form 4 for Jade Biosciences, Inc. (JBIO) on 01 May 2025.

Key facts

This page summarizes Eric Dobmeier's Form 4 filing for Jade Biosciences, Inc. (JBIO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 May 2025, 18:00.

Change

Previous filing in this sequence was filed on 01 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +23,017
Change %
Price: $0.000000
Shares after: 23,017
Date: 29 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,017
Exercise price: $10.14
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase 23,017 shares of the Issuer's common stock, which vests in full on the earlier of (i) April 29, 2026 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the recipient's continued service to the Issuer.